SELLAS Life Sciences Group, Inc.
SLS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001390478
No open-market purchases or sales by SELLAS Life Sciences Group, Inc. insiders were filed in the last 90 days; 193 institutions reported holding it in 13F filings for Q2 2026, worth $1.08B in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in SELLAS Life Sciences Group, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 112
- +19 vs. Q3 2025
- Shares held
- 35.5M
- +2.53M (+7.7%) vs. Q3 2025
- Total value
- $133.7M
- +$80.7M (+152.2%) vs. Q3 2025
- New holders
- 28
- 50 more added
- Sold out
- 9
- 18 more reduced
1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SLS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 193 | $1.08B |
| Q1 2026 | 160 | $228.4M |
| Q4 2025 | 112 | $133.7M |
| Q3 2025 | 94 | $53.1M |
| Q2 2025 | 79 | $58.7M |
| Q1 2025 | 45 | $15.5M |
| Q4 2024 | 31 | $6.47M |
| Q3 2024 | 33 | $6.76M |
| Q2 2024 | 30 | $4.86M |
| Q1 2024 | 30 | $7.82M |
| Q4 2023 | 31 | $3.72M |
| Q3 2023 | 28 | $4.54M |
| Q2 2023 | 25 | $4.91M |
| Q1 2023 | 22 | $4.28M |
| Q4 2022 | 29 | $4.46M |
| Q3 2022 | 28 | $4.42M |
| Q2 2022 | 26 | $6.64M |
| Q1 2022 | 26 | $11.3M |
| Q4 2021 | 27 | $9.59M |
| Q3 2021 | 30 | $17.1M |
| Q2 2021 | 29 | $21.3M |
| Q1 2021 | 31 | $13.3M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding SELLAS Life Sciences Group, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Barclays PLC | 511,034 | $1.93M | 0.00% | +328,354+179.7% | Added |
| DAGCO, Inc. | 577,540 | $2.18M | 0.50% | +577,540 | New |
| Morgan Stanley | 890,929 | $3.36M | 0.00% | −163,862−15.5% | Reduced |
| Northern Trust Corp | 930,750 | $3.51M | 0.00% | +199,575+27.3% | Added |
| Nuveen, LLC | 1,023,961 | $3.86M | 0.00% | +26,051+2.6% | Added |
| Two Sigma Investments, LP | 1,082,207 | $4.08M | 0.01% | +936,351+642.0% | Added |
| Marshall Wace, LLP | 1,340,668 | $5.05M | 0.00% | −1,017,331−43.1% | Reduced |
| Millennium Management LLC | 1,387,849 | $5.23M | 0.00% | +1,073,147+341.0% | Added |
| State Street Corp | 2,188,171 | $8.25M | 0.00% | +827,257+60.8% | Added |
| Geode Capital Management, LLC | 3,077,337 | $11.6M | 0.00% | +812,953+35.9% | Added |
| BlackRock, Inc. | 7,541,054 | $28.4M | 0.00% | +1,854,168+32.6% | Added |
| Vanguard Group Inc | 8,467,400 | $31.9M | 0.00% | +1,627,495+23.8% | Added |
| Anson Funds Management LP | 0 | $0 | 0.00% | −6,032,938−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −291,822−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −194,357−100.0% | Sold out |
| Prosperity Financial Group, Inc. | 0 | $0 | 0.00% | −18,500−100.0% | Sold out |
| Quadrature Capital Ltd | 0 | $0 | 0.00% | −16,579−100.0% | Sold out |
| Marshall Financial Group LLC | 0 | $0 | 0.00% | −10,309−100.0% | Sold out |
| Brooklyn FI, LLC | 0 | $0 | 0.00% | −10,240−100.0% | Sold out |
| Great Valley Advisor Group, Inc. | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −540−100.0% | Sold out |
| CIBC Bancorp USA Inc. | – | – | – | – | Not filed |